- Home
- JPC vs CPRX Comparison
JPC vs CPRX Comparison
Compare JPC & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- CPRX
- Stock Information
- Founded
- JPC 2003
- CPRX 2002
- Country
- JPC United States
- CPRX United States
- Employees
- JPC N/A
- CPRX N/A
- Industry
- JPC Investment Managers
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- CPRX Health Care
- Exchange
- JPC Nasdaq
- CPRX Nasdaq
- Market Cap
- JPC 2.6B
- CPRX 2.5B
- IPO Year
- JPC N/A
- CPRX 2006
- Fundamental
- Price
- JPC $8.01
- CPRX $22.24
- Analyst Decision
- JPC
- CPRX Strong Buy
- Analyst Count
- JPC 0
- CPRX 7
- Target Price
- JPC N/A
- CPRX $31.14
- AVG Volume (30 Days)
- JPC 998.5K
- CPRX 820.3K
- Earning Date
- JPC 01-01-0001
- CPRX 11-06-2024
- Dividend Yield
- JPC 7.57%
- CPRX N/A
- EPS Growth
- JPC N/A
- CPRX 114.68
- EPS
- JPC N/A
- CPRX 1.18
- Revenue
- JPC N/A
- CPRX $460,482,000.00
- Revenue This Year
- JPC N/A
- CPRX $23.98
- Revenue Next Year
- JPC N/A
- CPRX $18.27
- P/E Ratio
- JPC N/A
- CPRX $18.72
- Revenue Growth
- JPC N/A
- CPRX 32.17
- 52 Week Low
- JPC $5.94
- CPRX $13.12
- 52 Week High
- JPC $7.36
- CPRX $24.27
- Technical
- Relative Strength Index (RSI)
- JPC 41.59
- CPRX 54.94
- Support Level
- JPC $7.98
- CPRX $20.93
- Resistance Level
- JPC $8.11
- CPRX $22.49
- Average True Range (ATR)
- JPC 0.05
- CPRX 0.60
- MACD
- JPC -0.01
- CPRX 0.00
- Stochastic Oscillator
- JPC 10.53
- CPRX 77.06
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.